Flash Note: Q1 2025 Financial Figures
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) Increased by 32.4%
Paiania, 15 May 2025 – Lavipharm Group’s total earnings before interest, taxes, depreciation, and amortization (EBITDA) for the First Quarter of 2025 increased by 32.4%, amounting to EUR 3.77 million compared to EUR 2.85 million during the corresponding period of the previous year. EBITDA from continuing operations amounted to EUR 2.82 million compared to EUR 2.65 million in the same period last year.